A method of treating cardiac arrhythmia in a heart, including (i) determining that cardiac tissue is viable but with reduced innervation; and (ii) ablating the tissue to reduce a prevalence of arrhythmia in said heart. Optionally, the determining comprises detecting portions of heart wall which lack electrical activity. Optionally, at least some tissue which is viable but lacks nervous control is ablated, for example, to reduce or avoid arrhythmia.

Example systems and techniques for denervation, for example, renal denervation. In some examples, a processor determines one or more tissue characteristics of tissue proximate a target nerve and a blood vessel. The processor may generate, based on the one or more tissue characteristics, an estimated volume of influence of denervation therapy delivered by a therapy delivery device disposed within the blood vessel. The processor may generate a graphical user interface including a graphical representation of the tissue proximate the target nerve and the blood vessel and a graphical representation of the estimated volume of influence.

In order to enable more accurate calibration of brain, there is provided a system for creating a hemodynamic brain atlas for calibration of brain hemodynamics. The system comprises a non-invasive transcranial neurostimulation device, a non-invasive neuromonitoring device, and a computing device. The non-invasive transcranial neurostimulation device is configured to induce neuronal activity to evoke a hemodynamic response in a target region of interest (ROI) of a brain of a human subject. The non-invasive neuromonitoring device is configured to monitor the evoked hemodynamic response in the target ROI. The computing device configured to determine a set of parameters representing a hemodynamic response function, HRF, of the evoked hemodynamic response in the target ROI, and to associate the set of parameters of the HRF with the target ROI to form the hemodynamic brain atlas.

A method of treating cardiac arrhythmia in a heart, including (i) determining that cardiac tissue is viable but with reduced innervation; and (ii) ablating the tissue to reduce a prevalence of arrhythmia in said heart. Optionally, the determining comprises detecting portions of heart wall which lack electrical activity. Optionally, at least some tissue which is viable but lacks nervous control is ablated, for example, to reduce or avoid arrhythmia.

Described embodiments include a system, method, and computer program product. In a described system, a receiver circuit receives at least two reference images of a patient body part. Each reference image includes a respective landmark subsurface feature of the patient body part, and each imaged landmark subsurface feature has a respective spatial relationship to a respective region of a surface of the patient body part imaged during a medical examination. A feature matching circuit determines a correspondence between (x) each atlas landmark subsurface feature of the patient body part included in a landmark subsurface feature atlas and (y) each respective imaged landmark subsurface feature. A reporting circuit generates informational data reporting a depiction of an area of the surface of the patient body part by at least two adjacent imaged regions of the surface of the patient body part. A communication circuit outputs the informational data.

An image-guided system and method for performing needle biopsy on a moving lung nodule of a body is provided. CT images of the lung nodule are obtained to generate a motion model, based on which an optimal needle advancing path is determined. The motion of the lung nodule and the motion of a fiducial marker attached to the body are correlated. The motion of the fiducial marker is tracked and monitored by a camera to determine a position of the lung nodule based on the correlation. A time for advancing the needle is determined based on a motion attribute of the reference. The needle is advanced by a robotic needle manipulator at the predetermined time along the path to accomplish the needle placement.

The invention relates to a spinal navigation method. The method comprises the steps of providing a MRI, X-ray or CT based two-dimensional image of the spine of a subject and generating an ultrasound two-dimensional image using an ultrasound imaging device on the spine of said subject. Further, the method comprises the steps of matching the ultrasound two-dimensional image to the MRI, X-ray or CT based two-dimensional image, and relating a pre-specified segment of a spinal profile in the MRI, X-ray or CT based two-dimensional image to a corresponding segment in the ultrasound two-dimensional image.

A method for displaying a paranasal sinus region of a patient is executed at least in part on a computer, acquiring volume image data of the paranasal sinus region of the patient, identifying one or more airways within the paranasal sinus region from the volume image data, displaying the at least one or more airways, and highlighting one or more portions of the displayed airways that are constricted below a predetermined value.

A treatment method using a novel combination of non-invasive near infrared light (NIR)/laser therapy and the pharmacological agent ketamine, to more efficaciously upregulate neurotrophins and improve mitochondrial function. The NIR therapy is characterized by wavelengths of 200-2000 nm at surface wattage of 0.01-50.00 watts delivered by stationary emitters. The method can employ active circular motion techniques which involve moving the infrared light applicator manually, and/or by computer-controlled apparatus, conducted in conjunction with ketamine pharmacological therapy. In addition, a novel method of targeting NIR treatment of and characterizing central nervous system disorders using SPECT functional neuroimaging followed by quantitative analysis and a novel method of targeting NIR treatment of and characterizing spinal cord or nerve-related disorders using neurophysiological testing followed by quantitative analysis. Also, a novel method of using serial SPECT neuroimaging with quantitative analysis or using serial neurophysiological testing followed by quantitative analysis to elucidate changes in response to treatment.

A treatment method using a novel combination of non-invasive near infrared light (NIR)/laser therapy and the pharmacological agent ketamine, to more efficaciously upregulate neurotrophins and improve mitochondrial function. The NIR therapy is characterized by wavelengths of 200-2000 nm at surface wattage of 0.01-50.00 watts delivered by stationary emitters. The method can employ active circular motion techniques which involve moving the infrared light applicator manually, and/or by computer-controlled apparatus, conducted in conjunction with ketamine pharmacological therapy. In addition, a novel method of targeting NIR treatment of and characterizing central nervous system disorders using SPECT functional neuroimaging followed by quantitative analysis and a novel method of targeting NIR treatment of and characterizing spinal cord or nerve-related disorders using neurophysiological testing followed by quantitative analysis. Also, a novel method of using serial SPECT neuroimaging with quantitative analysis or using serial neurophysiological testing followed by quantitative analysis to elucidate changes in response to treatment.